ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ZVSA

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/25	06:05	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2025/01/18	06:05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/12/30	22:30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/12/27	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/12/21	07:04	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/12/21	06:15	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/12/18	21:55	GlobeNewswire Inc.	ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/20	21:55	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/15	22:35	GlobeNewswire Inc.	Life Sciences Investor Forum: Presentations Now Available for Online Viewing	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/14	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/14	22:10	GlobeNewswire Inc.	ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/14	22:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/06	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/11/05	21:00	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/31	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/29	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/22	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/17	20:50	GlobeNewswire Inc.	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/15	20:50	GlobeNewswire Inc.	ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/10/07	20:55	GlobeNewswire Inc.	ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/17	06:30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/17	06:29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	20:25	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	20:22	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:35	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:32	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/10	05:30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/09/04	06:29	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ZVSA	ZyVersa Therapeutics Inc